The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., & DeMets, D. L. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33525-0 · Cited by 1,249
Cited by
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Kern, T. S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/95103 · Cited by 614
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
Immunological mechanisms in the pathogenesis of diabetic retinopathy
Adamis, A. P., & Berman, A. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0111-x · Cited by 322
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 269
Sohn, H. J., Han, D. H., Kim, I. T., Oh, I. K., Kim, K. H., Lee, D. Y., & Nam, D. H. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.03.033 · Cited by 265
Hypoxia-inducible factors and diabetes
Gunton, J. E. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137556 · Cited by 159
“Neutralizing antibodies directed against VEGF have markedly improved outcomes for proliferative diabetic retinopathy and for “wet” macular edema (126, 127), showing that this pathway is clinically important in human retinopathy.”
BackgroundGeorgopoulos, M., Polak, K., Prager, F., Prunte, C., & Schmidt-Erfurth, U. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.138479 · Cited by 124
Metadata
- Authors
- Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 114
- Issue
- 4
- Pages
- 743-750
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2151129590
- Cited by
- 335
- References
- 33
- FWCI
- 47.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.